Department of Pharmacy, The Third People's Hospital of Changzhou, Changzhou City, Jiangsu Province 213001, China.
Department of Gastroenterology, The Third People's Hospital of Changzhou, 300 Lanling North Road, Changzhou City, Jiangsu 213001, China.
Anal Cell Pathol (Amst). 2021 Jun 22;2021:5510111. doi: 10.1155/2021/5510111. eCollection 2021.
The role of long noncoding RNAs- (lncRNAs-) associated competing endogenous RNA (ceRNA) in the field of hepatocellular carcinoma (HCC) biology is well established, but the involvement of lncRNAs competing interactions in the progression of liver cirrhosis to HCC is still unclear. We aimed to explore the differential expression profiles of lncRNAs, microRNAs (miRNA), and messenger RNAs (mRNAs) to construct a functional ceRNA network in cirrhotic HCC. The lncRNA, miRNA, and mRNA expression datasets were obtained from Gene Expression Omnibus and The Cancer Genome Atlas. Based on miRanda and TargetScan, the HCC-specific ceRNA network was constructed to illustrate the coexpression regulatory relationship of lncRNAs, miRNAs, and mRNAs. The potential prognostic indicators in the network were confirmed by survival analysis and validated by qRT-PCR. A total of 74 lncRNAs, 36 intersection miRNAs, and 949 mRNAs were differentially expressed in cirrhotic HCC samples compared with cirrhosis samples. We constructed a ceRNA network, including 47 lncRNAs, 35 miRNAs, and 168 mRNAs. Survival analysis demonstrated that 2 lncRNAs (EGOT and SERHL), 4 miRNAs, and 40 mRNAs were significantly associated with the overall survival of HCC patients. Two novel regulatory pathways, EGOT-miR-32-5p-XYLT2 axis and SERHL-miR-1269a/miR-193b-3p-BCL2L1/SYK/ARNT/CHST3/LPCAT1 axis, were built up and contribute to the underlying mechanism of HCC pathogenesis. The higher-expressed SERHL was associated with a higher risk of all-cause death. The expressions of SERHL-miR-1269a-BCL2L1 were significantly different using qRT-PCR in vitro studies. lncRNAs EGOT and SERHL might serve as effective prognostic biomarkers and potential therapeutic targets in cirrhotic HCC treatment.
长链非编码 RNA(lncRNA)相关竞争内源性 RNA(ceRNA)在肝细胞癌(HCC)生物学领域的作用已得到充分证实,但 lncRNA 竞争相互作用在肝硬化向 HCC 进展中的参与仍不清楚。我们旨在探索 lncRNA、微小 RNA(miRNA)和信使 RNA(mRNA)的差异表达谱,构建肝硬化 HCC 中的功能性 ceRNA 网络。lncRNA、miRNA 和 mRNA 表达数据集从基因表达综合数据库和癌症基因组图谱获得。基于 miRanda 和 TargetScan,构建 HCC 特异性 ceRNA 网络,以说明 lncRNA、miRNA 和 mRNA 的共表达调控关系。通过生存分析和 qRT-PCR 验证,验证网络中的潜在预后指标。与肝硬化样本相比,肝硬化 HCC 样本中共有 74 个 lncRNA、36 个交集 miRNA 和 949 个 mRNA 差异表达。我们构建了一个包括 47 个 lncRNA、35 个 miRNA 和 168 个 mRNA 的 ceRNA 网络。生存分析表明,2 个 lncRNA(EGOT 和 SERHL)、4 个 miRNA 和 40 个 mRNA 与 HCC 患者的总生存率显著相关。构建了两个新的调控通路,即 EGOT-miR-32-5p-XYLT2 轴和 SERHL-miR-1269a/miR-193b-3p-BCL2L1/SYK/ARNT/CHST3/LPCAT1 轴,有助于阐明 HCC 发病机制的潜在机制。高表达的 SERHL 与全因死亡风险增加相关。体外研究中 qRT-PCR 显示 SERHL-miR-1269a-BCL2L1 的表达差异显著。lncRNA EGOT 和 SERHL 可能作为肝硬化 HCC 治疗中有效的预后生物标志物和潜在治疗靶点。